Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Tumor Biology
Erschienen in: Tumor Biology 5/2010

01.10.2010 | Research Article

Polymorphisms of Lewis and Secretor genes are related to breast cancer and metastasis in axillary lymph nodes

verfasst von: Debora Barreto Teresa, Raquel Alves Santos, Catarina Satie Takahashi, Helio H. Carrara, Haroldo W. Moreira, Luis Carlos Mattos, Nicolino Lia-Neto, Leonardo A. Cunha, Carmem Lucia Bassi, Edson Garcia Soares, Eduardo Antonio Donadi, Elaine Rodrigues Mello, Christiane Pienna Soares

Erschienen in: Tumor Biology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

ABH and Lewis antigen expression has been associated with cancer development and prognosis, tumor differentiation, and metastasis. Considering that invasive ductal breast carcinoma (IDC) presents multiple molecular alterations, the aim of the present study was to determine whether the polymorphism of ABO, Lewis, and Secretor genes, as well as ABO phenotyping, could be associated with tumor differentiation and lymph nodes metastasis. Seventy-six women with IDC and 78 healthy female blood donors were submitted to ABO phenotyping/genotyping and Lewis and Secretor genotyping. Phenotyping was performed by hemagglutination and genotyping by the polymerase chain reaction with sequence-specific primers. ABO, Lewis, and Secretor genes were classified by individual single nucleotide polymorphism at sites 59, 1067, 202, and 314 of the Lewis gene, 428 of the Secretor gene, and 261 (O1 allele), 526 (O2 and B allele), and 703 (B allele). No association was found between breast cancer and ABO antigen expression (P = 0.9323) or genotype (P = 0.9356). Lewis-negative genotype was associated with IDC (P = 0.0126) but not with anatomoclinical parameters. Nonsecretor genotype was associated with axillary lymph node metastasis (P = 0.0149). In conclusion, Lewis and Secretor genotyping could be useful to predict respectively breast cancer susceptibility and axillary lymph nodes metastasis.
Literatur
1.
Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist. 2006;11:541–52.CrossRefPubMed
2.
3.
Hakomori SI, Koscielak J, Bloch KJ, Jeanloz RW. Immunologic relationship between blood group substances and a fucose-containing glycolipid of human adenocarcinoma. J Immunol. 1967;98:31–8.PubMed
4.
Marionneau S, Cailleau-Thomas A, Rocher J, Moullac-Vaidye B, Ruvoën N, Clément M, et al. ABH and Lewis histo-blood group antigens, a model for the meaning of oligosaccharide diversity in the face of a changing world. Biochimie. 2001;83:565–73.CrossRefPubMed
5.
Koda Y, Tachida H, Pang H, Liu Y, Soejima M, Ghaderi AA, et al. Contrasting patterns of polymorphisms at the ABO-secretor gene (FUT2) and plasma alpha(1, 3)fucosyltransferase gene (FUT6) in human populations. Genetics. 2001;158:747–56.PubMed
6.
Liu Y, Koda Y, Soejima M, Pang H, Schlaphoff T, Du Toit E, et al. Extensive polymorphism of the FUT2 gene in an African (Xhosa) population of South Africa. Hum Genet. 1998;103:204–10.CrossRefPubMed
7.
Kelly RJ, Rouquier S, Giorgi D, Lennon GG, Lowe JB. Sequence and expression of a candidate for the human Secretor blood group alpha(1, 2)fucosyltransferase gene(FUT2). Homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the non-secretor phenotype. J Biol Chem. 1995;270:4640–9.CrossRefPubMed
8.
Soejima M, Pang H, Koda Y. Genetic variation of FUT2 in a Ghanaian population: identification of four novel mutations and inference of balancing selection. Ann Hematol. 2007;86:199–204.CrossRefPubMed
9.
Nishihara S, Narimatsu H, Iwasaki H, Yazawa S, Akamatsu S, Ando T, et al. Molecular genetic analysis of the human Lewis histo-blood group system. J Biol Chem. 1994;269:29271–8.PubMed
10.
Salmon C. Les groupes sanguins ou l´ecriture des genes. Editorial Masson 1997.
11.
Matzhold EM, Helmberg W, Wagner T, Drexler C, Ulrich S, Winkler A, et al. Identification of 14 new alleles at the fucosyltransferase 1, 2, and 3 loci in Styrian blood donors. Transfusion. 2009;49:2097–108.CrossRefPubMed
12.
Liu TC, Chang JG, Lin SF, et al. Lewis (FUT3) genotypes in Taiwanese, Thai, and Filipino populations. Ann Hematol. 2000;79:599–603.CrossRefPubMed
13.
Salomaa V, Pankow J, Heiss G, Cakir B, Eckfeldt JH, Ellison RC, et al. Genetic background of Lewis-negative blood group phenotype and its association with atherosclerotic disease in the NHLBI Family Heart Study. J Intern Med. 2000;247:689–98.CrossRefPubMed
14.
Hakomori S. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta. 1999;1473:247–66.PubMed
15.
Moreno A, Campi C, Escovich L, García-Borrás S, Racca L, Racca A, et al. Analysis of the FUT2 gene and Secretor status in patients with oral lesions. Inmunología. 2009;28:131–4.
16.
Thorven M, Grahn A, Hedlund KO, Johansson H, Wahlfrid C, Larson G, et al. A homozygous nonsense mutation (428G/A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J Virol. 2005;79:15351–5.CrossRefPubMed
17.
Larsson MM, Rydell GE, Grahn A, Rodriguez-Diaz J, Akerlind B, Hutson AM, et al. Antibody prevalence and titer to norovirus (genogroup II) correlate with secretor (FUT2) but not with ABO phenotype or Lewis (FUT3) genotype. J Infect Dis. 2006;194:1422–7.CrossRefPubMed
18.
Marionneau S, Airaud F, Bovin NV, Le Pendu J, Ruvoen-Clouet N. Influence of the combined ABO, FUT2, and FUT3 polymorphism on susceptibility to Norwalk virus attachment. J Infect Dis. 2005;192:1071–7.CrossRefPubMed
19.
Kindberg E, Hejdeman B, Bratt G, Wahren B, Lindblom B, Hinkula J, et al. A nonsense mutation (428G/A) in the fucosyltransferase FUT2 gene affects the progression of HIV-1 infection. AIDS. 2006;20:685–9.CrossRefPubMed
20.
Madhavan M, Srinivas P, Abraham E, Ahmed I, Vijayalekshmi NR, Balaram P. Down regulation of endothelial adhesion molecules in node positive breast cancer: possible failure of host defence mechanism. Pathol Oncol Res. 2002;8:125–8.CrossRefPubMed
21.
Gong Y, Sun X, Huo L, Wiley EL, Rao MS. Expression of cell adhesion molecules, CD44s and E-cadherin, and microvessel density in invasive micropapillary carcinoma of the breast. Histopathol. 2005;46:24–30.CrossRef
22.
Vengelen-Tyler V. Technical manual, 12th edn. American Association of Blood Banks, 1996.
23.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human erythrocytes. Nucleic Acids Res. 1998;16:1215.CrossRef
24.
Procter J, Crawford J, Bunce M, Welsh KI. A rapid molecular method (polymerase chain reaction with sequence-specific primers) to genotype for ABO blood group and secretor status and its potential for organ transplants. Tissue Antigens. 1997;50:475–83.CrossRefPubMed
25.
Grahn A, Elmgren A, Aberg L, et al. Determination of Lewis FUT3 gene mutations by PCR using sequence-specific primers enables efficient genotyping of clinical simples. Hum Mutat. 2001;18:358–9.CrossRefPubMed
26.
Cakir B, Pankow JS, Samomaa V, et al. Distribution of Lewis (FUT3) genotype and allele: frequencies in a biethnic United State population. Ann Hematol. 2002;81:558–65.CrossRefPubMed
27.
Karlsson KA. Meaning and therapeutic potential of microbial recognition of host glycoconjugates. Mol Microbiol. 1998;29:1–11.CrossRefPubMed
28.
Garrison RJ, Havlik RJ, Harris RB, Feinleib M, Kannel WB, Padgett SJ. ABO blood group and cardiovascular disease: the Framingham study. Atherosclerosis. 1976;25:311–8.CrossRefPubMed
29.
Souto JC, Almasy L, Muniz-Diaz E, Soria JM, Borell M, Bayen L, et al. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol. 2000;20:2024–8.PubMed
30.
Johansson I, Bratt P, Hay DI, Schluckebier S, Stromberg N. Adhesion of Candida albicans, but not Candida krusei, to salivary statherin and mimicking host molecules. Oral Microbiol Immunol. 2000;15:112–8.CrossRefPubMed
31.
Ilver D, Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET. Helicobacter pylori adhesion binding fucosylated histo-blood group antigens revealed by retagging. Science. 1998;279:373–7.CrossRefPubMed
32.
Moldvay J, Scheid P, Wild P, Nabil K, Siat J, Borrelly J, et al. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res. 2000;6:1125–234.PubMed
33.
Dresler CM, Ritter JH, Wick MR, Roper CL, Patterson GA, Cooper JD. Immunostains for blood group antigens lack prognostic significance in T1 lung carcinoma. Ann Thorac Surg. 1995;59:1069–73.CrossRefPubMed
34.
Bryne M, Eide GE, Lilleng R, Langmark F, Thrane PS, Dabelsteen E. A multivariate study of the prognosis of oral squamous cell carcinoma. Are blood group and hemoglobin new prognostic factors? Cancer. 1991;68:1994–8.CrossRefPubMed
35.
Nakagoe T, Fukushima K, Nanashima A, Sawai T, Tsuji T, Jibiki MA, et al. Comparison of the expression of ABH/Lewis-related antigens in polypoid and non-polypoid growth types of colorectal carcinoma. J Gastroenterol Hepatol. 2001;16:176–83.CrossRefPubMed
36.
You WC, Ma JL, Liu WD, Gail MH, Chang YS, Zhang L, et al. Blood type and family cancer history in relation to precancerous gastric lesions. Int J Epidemiol. 2000;29:405–7.CrossRefPubMed
37.
Pyd M, Rzewnicki I, Suwayach U. ABO blood groups in patients with laryngeal and hypopharyngeal cancer. Otolaryngol Pol. 1995;49:396–8.PubMed
38.
Pinkston JA, Cole P. ABO blood groups and salivary gland tumors (Alabama, United States). Cancer Causes Control. 1996;7:572–4.CrossRefPubMed
39.
Nozoe T, Ezaki T, Baba H, Kakeji Y, Maehara Y. Correlation of ABO blood group with clinicopathologic characteristics of patients with esophageal squamous cell carcinoma. Dis Esophagus. 2004;17:146–9.CrossRefPubMed
40.
Dandona M, Gao F, Linehan DC, Wang-Gillam A. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 2010;102:135–6.CrossRefPubMed
41.
Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009;41(9):986–90.CrossRefPubMed
42.
Adamian RT. Blood-type and rhesus distribution in Armenian women with endometrial carcinoma. Vopr Onkol. 2005;51:575–6.PubMed
43.
Vogel F. ABO blood groups and disease. Am J Hum Genet. 1970;22:465–75.
44.
Tursen U, Tiftik EN, Unal S, Gunduz O, Kaya TI, Camdeviren H, et al. Relationship between ABO blood groups and skin cancers. Dermatol Online J. 2005;11:44.PubMed
45.
Su M, Lu SM, Tian DP, Zhao H, Li XY, Li DR, et al. Relationship between ABO blood groups and carcinoma of esophagus and cardia in Chaosan inhabitants of China. World J Gastroenterol. 2001;7:657–61.PubMed
46.
Marionneau S, Moullac-Vaidye B, Le Pendu J. Expression of histo-blood group A antigen increases resistance to apoptosis and facilitates escape from immune control of rat colon carcinoma cells. Glycobiol. 2002;12:851–6.CrossRef
47.
Mackenzie IC, Dabelsteen E, Rittman G, Junggren L, TOH H. Expression of blood group-related glycoconjugates in the junctional and other oral epithelia of rodents. Anat Rec. 1995;241:310–8.CrossRefPubMed
48.
49.
Nishihara S, Narimatsu H, Iwasaki H, et al. Molecular genetic analysis of the human Lewis histo-blood group system. J Biol Chem. 1994;269:292718.
50.
Narimatsu H, Iwasaki H, Nishihara S, et al. Genetic evidence for the Lewis enzyme, which synthesizes type-1 Lewis antigens in colon tissue, and intracellular localization of the enzyme. Cancer Res. 1996;56:330–8.PubMed
51.
Jiang JM, Pan KF, Ma JL, Ning T, You LuGR, WC Ke Y. Analysis of Lewis gene polymorphism in high and low incidence area of gastric cancer in Shandong province. Yi Chuan. 2003;25:258–60.PubMed
52.
Kawaguchi T. Cancer metastasis: characterization and identification of the behavior of metastatic tumor cells and the cell adhesion molecules, including carbohydrates. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:39–64.CrossRefPubMed
53.
Kabayama K, Ito N, Honke K, Igarashi Y, Inokuchi J. Suppression of integrin expression and tumorigenicity by sulfation of lactosylceramide in 3LL Lewis lung carcinoma cells. J Biol Chem. 2001;276:26777–83.CrossRefPubMed
54.
Mizuguchi S, Nishiyama N, Iwata T, Nishida T, Izumi N, Tsukiota T, et al. Clinical value of serum cytokeration 19 fragment and sialyl-Lewis x in non-small cell lung cancer. Ann Thorac Surg. 2007;83:216–21.CrossRefPubMed
55.
Ohyama C, Kanto S, Kato K, Nakano O, Arai Y, Kato T, et al. Natural killer cells attack tumor cells expressing high levels of sialyl Lewis x oligosaccharides. Proc Natl Acad Sci USA. 2003;99:13789–94.CrossRef
56.
Oberhuber G, Kranz A, Dejaco C, Dragosics B, Mosberger I, Mayr W, et al. Blood groups Lewis (b) and ABH expression in gastric mucosa: lack of inter-relation with Helicobacter pylori colonization and occurrence of gastric MALT lymphoma. Gut. 1997;41:37–42.CrossRefPubMed
57.
Aubert M, Panicot L, Crotte C, Gibier P, Lombardo D, Sadoulet MO, et al. Restoration of alpha(1, 2) focosyltransferase activity decreases adhesive and metastatic properties of human pancreatic cancer cells. Cancer Res. 2000;60:1449–56.PubMed
58.
Gorelik E, Xu F, Henion T, Anaraki F, Galili U. Reduction of metastatic properties of BL6 melanoma cells expressing terminal fucose(alpha)1-2-galactose after alpha1, 2-fucosyltransferase cDNA transfection. Cancer Res. 1997;57:332–6.PubMed
59.
Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jotgensen J, Wolf H, et al. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem. 1999;45:54–61.PubMed
60.
Lamey P-J, Douglas PS, Napier SS. Secretor status and oral cancer. Br J Oral Maxil Surg. 1994;32:214–7.CrossRef
61.
Cerović R, Juretić M, Balen S, Belusić M, Caser L, Rogić M. Examining the presence of ABO(H) antigens of blood types in the saliva of patients with oral cancer. Coll Antropol. 2008;32:509–12.PubMed
62.
Jiang JM, Pan KF, Ma JL, Ning T, You LuGR, WC Ke Y. Analysis of polymorphisms on Lewis blood group antigen related Se gene in the populations in Shandong with high-risk of gastric cancer and Beijing. Yi Chuan. 2003;25:261–6.PubMed
63.
Vidas I, Delajlija M, Temmer-Vuksan B, Stipetic-Mravak M, Cindric N, Maricic D. Examining the secretor status in the saliva of patients with oral pre-cancerous lesions. J Oral Rehab. 1999;26:177–82.CrossRef
Metadaten
Titel
Polymorphisms of Lewis and Secretor genes are related to breast cancer and metastasis in axillary lymph nodes
verfasst von
Debora Barreto Teresa
Raquel Alves Santos
Catarina Satie Takahashi
Helio H. Carrara
Haroldo W. Moreira
Luis Carlos Mattos
Nicolino Lia-Neto
Leonardo A. Cunha
Carmem Lucia Bassi
Edson Garcia Soares
Eduardo Antonio Donadi
Elaine Rodrigues Mello
Christiane Pienna Soares
Publikationsdatum
01.10.2010
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2010
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0048-2

Weitere Artikel der Ausgabe 5/2010

Tumor Biology 5/2010 Zur Ausgabe

Research Article

Synthesis and structural characterization of the peptide epitope of the ovarian cancer biomarker CA125 (MUC16)

Research Article

Alkaloids extracted from Pterogyne nitens induce apoptosis in malignant breast cell line

Research Article

AFP computational secreted network construction and analysis between human hepatocellular carcinoma (HCC) and no-tumor hepatitis/cirrhotic liver tissues

Research Article

Up-regulation of EphA2 and down-regulation of EphrinA1 are associated with the aggressive phenotype and poor prognosis of malignant glioma

Research Article

Downregulation of tapasin expression in primary human oral squamous cell carcinoma: association with clinical outcome

Research Article

BAG3 protein delocalisation in prostate carcinoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise